Investing.com - Financial Markets Worldwide

MapLight Therapeutics IPO reportedly well oversubscribed

AuthorVlad Schepkov
Published 20/10/2025, 16:06
© Reuters.
JEF
0.08%
SF
-0.15%
(Updated - October 20, 2025 10:53 AM EDT)

MapLight Therapeutics Inc.’s (MPLT) Nasdaq IPO has attracted orders exceeding the available shares ahead of its scheduled pricing on October 26, according to a Bloomberg report on Monday.

The central nervous system disorders-focused biotech company is offering 14.75 million shares at $17 each to raise $250.8 million. The company expected to stop taking orders Thursday after markets close in New York.

Due to the federal government shutdown and MapLight seeking automatic effectiveness of its registration statement 20 days after filing terms on October 6, the offering is scheduled to price on October 26, according to a management presentation. The company may reconsider the use of automatic effectiveness if the federal government and SEC resume normal operations before that date.

Morgan Stanley, Jefferies Financial Group Inc., Leerink Partners and Stifel Financial Corp. are working on the offering.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.